US · Healthcare · Biotechnology
EPS came in at -1.33 against a street estimate of -1.47 — a beat of 9.5%.
Analysts rate Celcuity LLC a strong buy (13 buy, 0 hold, 0 sell out of 13) with an average price target of $152.72.
| Fund | Stake |
|---|---|
| Baker Bros Advisors LP | 16.18% |
| venBio Select Advisor LLC | 6.95% |
| RTW INVESTMENTS, LLC | 6.75% |
| Perceptive Advisors LLC | 6.53% |
| BlackRock Inc | 6.17% |
| State Street Corp | 4.00% |
| Vanguard Capital Management, LLC | 3.83% |
| NEA Management Company, LLC | 3.50% |
| Document | Date |
|---|---|
| Quarterly report · Q3 2026 HEADLINE NUMBERS • Celcuity reported a net loss of $73.337 million for the three months ended September 30, 2026, compared with $43.804 million in th | 2026-11-05 |
| Results announced · Q4 2026 HEADLINE NUMBERS • Q3 2026 net loss was $73.3 million, or $1.33 per share, compared with $43.8 million, or $0.92 per share, in Q3 2025. • Non-GAAP a | 2026-11-05 |
| Board / officer change · Q4 2026 HEADLINE NUMBERS • Celcuity increased its Board of Directors from eight members to nine. • David W. Gryska was appointed as an independent director, | 2026-10-02 |
| Reg FD disclosure · Q3 2026 HEADLINE NUMBERS • Celcuity announced on September 30, 2026, that REVTORPYK™ (gedatolisib) is commercially available in the United States. • The pro | 2026-09-30 |
| Reg FD disclosure · Q3 2026 CELCUITY INC. - 8-K SUMMARY HEADLINE NUMBERS • Company: Celcuity Inc. (Nasdaq ticker: CELC) • Incorporation: Delaware • Principal location: 2800 Cam | 2026-08-26 |
| Quarterly report · Q2 2026 CELCUITY INC. — 10-Q SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Cash & Investments: $754.0 million as of June 30, 2026 (up from $441.5 million | 2026-08-13 |
| Results announced · Q3 2026 CELCUITY INC. – Q2 2026 FINANCIAL RESULTS SUMMARY --- HEADLINE NUMBERS • Q2 2026 net loss: $78.9 million ($1.44 per share) vs. Q2 2025 net loss of | 2026-08-13 |
| Reg FD disclosure · Q3 2026 CELCUITY INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • FDA Approval Date: July 14, 2026 • Drug Approved: REVTORPYK™ (gedatolisib) • Commercial Launch T | 2026-07-15 |
Readable in the app.
| Announcement | Date |
|---|---|
| FDA approval of REVTORPYK for HR+/HER2- breast cancer treatment Celcuity announced major milestones for REVTORPYK (gedatolisib), its breast cancer treatment drug. The FDA approved REVTORPYK on July 14, 2026, for HR+/HER2- breast cancer patients without P | 2026-08-13 |
| FDA Approval of REVTORPYK for HR+/HER2- Breast Cancer Treatment Celcuity announced FDA approval of REVTORPYK (gedatolisib), a breakthrough cancer drug for treating hormone receptor-positive, HER2-negative breast cancer without PIK3CA mutations. This is a | 2026-07-15 |
| FDA accepts NDA for gedatolisib with Priority Review, PDUFA goal date July 2026 Celcuity announced major milestones for its cancer drug gedatolisib. The FDA accepted the company's application for the drug and granted Priority Review with an approval target of July 17, 2 | 2026-03-25 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Celcuity LLC — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.